Regenxbio公司公布的最新数据显示,其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实,患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。
这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据,表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发,以评估其长期安全性与疗效。
Regenxbio公司公布的最新数据显示,其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实,患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。
这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据,表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发,以评估其长期安全性与疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.